|05th December,2018||4:00-5:30 pm||Track 2|
Bringing new therapies to treat rare diseases requires more than scientific innovation. Innovation in business models and incubation financing is critical as the need to find ways to cost effectively develop new medication is becoming highly important. Initiatives like collaboration centres and rare disease centres try to take the best of both worlds by implementing multidimensional approaches to address the needs of the rare disease community. In addition to conducting their own research, collaborative models that feature pharmaceutical companies, academic institutions, start-ups, and patient groups are now being put in place.
Anjan Aralihalli - CTI Life Sciences Fund II
Bertrand Verwee - ROCHE